The impact of concomitant pulmonary infection on immune dysregulation in Pneumocystis jirovecii pneumonia

BMC Pulmonary Medicine

Table 1 Demographic and clinical characteristics of 65 patients with PJP

	Pure PJP	Mixed PJP	P value
Gender(M/F)	25/22	9/9	0.818
Age, years	49.1 ± 16.0	50.6 ± 17.7	0.587
Underlying diseases
Hematological malignancy s/p chemotherapy	6	2
Allogeneic peripheral blood stem cell transplantation	3	2
Solid organ transplantation (kidney/heart/liver/pancreas/pancreas-kidney)	19/4/2/1/1	3/0/0/0/0
Connective tissue diseases with immunosuppresants	6	2
Glomerulonephritis with immunosuppresants	3	6
Prostate cancer with immunosuppresants	1	0
Breast cancer with immunosuppresants	0	1
Long-term steroid therapy	1	1
DM	0	1
PaO₂/FiO₂ before BAL	230.0(182.2;278.7)	245.4(158.3;322.9)	0.631
APACHE II scores	23.00(18.00;27.50)	23.50(20.25;26.50)	0.987
ICU admission, case number (%)	23(48.9)	12(66.7)	0.269
ICU length of stay (days)	19.0(7.3;24.0)	11.0(6.3;21.3)	0.456
Ventilator needed, case number (%)	24(51.1)	11(61.1)	0.667
Death, case number (%)	19(40.4)	10(55.6)	0.403

Data are expressed as case number and % in parenthesis or median IQR (25%;75%).
PJP = Pneumocystis jirovecii pneumonia; Mixed PJP = PJP with concurrent other pulmonary infections; PaO₂ = arterial oxygen tension; FiO₂ = fraction of inspired oxygen; ICU = intensive care unit; BAL = bronchoalveolar lavage; APACHE = Acute Physiology and Chronic Health Evaluation.

ISSN: 1471-2466